AzurRx BioPharma, Inc. (NASDAQ:AZRX) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
using the corporate presentation materials attached hereto as
Exhibit 99.1, which presentation is posted on the Companys
website located at www.azurrx.com. The Company may continue to
use these materials from time to time in conversations with
investors and analysts.
information contained in Item 7.01 of this Current Report on Form
8-K, including Exhibit 99.1 attached hereto, shall not be deemed
“filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities
of that Section. The information in Item 7.01 of this Current
Report on Form 8-K shall not be incorporated by reference into
any filing or other document to the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
reference in such filing or document.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Corporate Presentation
|
About AzurRx BioPharma, Inc. (NASDAQ:AZRX)
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD). AzurRx BioPharma, Inc. (NASDAQ:AZRX) Recent Trading Information
AzurRx BioPharma, Inc. (NASDAQ:AZRX) closed its last trading session at with 13,207 shares trading hands.
